Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE ‐1 and EVOLVE ‐2
Headache: The Journal of Head and Face Pain · 2024
DOI: 10.1111/head.14652 ↗At a glance
Randomisierte kontrollierte Studie in Headache: The Journal of Head and Face Pain, 2024. Written by E Anne MacGregor and 5 co-authors. Institution: Centre for Reproductive Medicine, St Bartholomew's Hospital, London, UK. Major MEDLINE topics: Quality of Life, Migraine Disorders, Antibodies, Monoclonal, Humanized. Cited 7 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Eli Lilly and Company.
Abstract (original language)
Background
We evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually related migraine (MRM).
Methods
Patients were identified post hoc from three double‐blind, randomized, phase 3 clinical trials in patients with episodic migraine. Patients completed a 1‐month prospective baseline period and up to 6 months (EVOLVE‐1 and ‐2, studies pooled) of double‐blind treatment with galcanezumab (120 mg/month) or placebo. Menses and headache information were recorded by electronic daily diary. Patients with a migraine attack starting during the 5‐day perimenstrual interval (first day of bleeding ± 2 days) for ≥2 of their first three diary‐recorded menstrual cycles were categorized as having MRM. The primary efficacy measure was mean change in monthly migraine headache days from baseline, averaged over Months 4 through 6. Response rates, change in monthly perimenstrual migraine headache days, monthly non‐perimenstrual migraine headache days, and quality of life were also assessed.
Results
Post hoc MRM analysis criteria were met by 462/1133 women (41%). Mean (standard deviation) baseline monthly migraine headache days were 9.7 (±3.1; n = 146) for galcanezumab‐treated patients and 9.6 (±2.8; n = 316) for placebo‐treated patients. The mean change (standard error [SE]) in migraine headache days over Months 4 through 6 was −5.1 days (±0.39) for galcanezumab versus −3.2 (±0.35) for placebo ( p < 0.001). The mean change (SE) in perimenstrual migraine headache days over Months 4 through 6 was −0.75 days (±0.08) for galcanezumab versus −0.49 (±0.07) for placebo ( p = 0.004). For migraine headache days outside the perimenstrual period, the mean change in migraine headache days was −4.6 (±0.38) for galcanezumab and −2.8 (±0.33) for placebo ( p < 0.001). Improvements in response rates and the Migraine‐Specific Quality of Life Questionnaire were also observed over Months 4 through 6.
Conclusion
Galcanezumab was effective for migraine prevention in women with MRM.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centre for Reproductive Medicine, St Bartholomew's Hospital, London, UK.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Albert Einstein College of Medicine, Montefiore Headache Center, Bronx, New York, USA.
ORCID profiles: E Anne MacGregor, Holland C Detke
Funding
- Eli Lilly and Company
Cite
APA
MacGregor, E. A., Okonkwo, R., Detke, H. C., Polavieja, P., Fernandes, M. S., & Pavlovic, J. M. (2024). Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE ‐1 and EVOLVE ‐2. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14652
Vancouver
MacGregor EA, Okonkwo R, Detke HC, Polavieja P, Fernandes MS, Pavlovic JM. Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE ‐1 and EVOLVE ‐2. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14652
BibTeX
@article{MacGregor2024,
author = {MacGregor, E Anne and Okonkwo, Rose and Detke, Holland C and Polavieja, Pepa and Fernandes, Maria S and Pavlovic, Jelena M},
title = {Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE ‐1 and EVOLVE ‐2},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
doi = {10.1111/head.14652}
}
EUVIMED